PharmaUnited States Coverage Without Uptake: Vertex’s Non-Opioid Journavx Passes 1 Million Scripts, $29M in Sales The first new-class painkiller in decades has near-universal US coverage and negligible sales — and no clear path to Latin American patients. By Fernando PafumiSep 14, 20264 Comments
IHME: Global Health Funding Falls Another 5% in 2026 After Hitting Lowest Level Since 2012 Nov 16, 2026
You must be logged in to post a comment.